A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.

Inclusion Criteria: * Patients who participated in LAM-IV-301, LAM-IV-303, LAM-IV-307 OR LAM-IV-308 and received lanthanum carbonate * Patients must continue to require treatment with a phosphate binder for hyperphosphatemia * male or non-pregnant female who agrees to use an effective contraceptive method while on study treatment and for 30 days thereafter Exclusion Criteria: * Patients withdrawn from LAM-IV-301, LAM-IV-303 OR LAM-IV-307 prior to randomization * Patients withdrawn from LAM-IV-301, LAM-IV-303, LAM-IV-307 OR LAM-IV-308 due to adverse events termed "possible" or "related" to study medication * Pregnant or lactating women